Services / Activities

- Certified Clinical Trial Centres with harmonized procedures (SOPs), quality control and qualified personnel


- Feasibility assessment for centre participation and recruitment (performed at short notice)


- Help in achieving recruitment rate by contacting directly and regularly the participating centres


- Scientific advice including contributions to clinical trial design


- Certification and training of technical personnel


- Facilitation of administrative setup of contracts with Clinical Trial Centres


- Subspecialty clinical trial research networks


- Access to the Reading Centre Network

Alliances and Partnerships is an ECRIN-ERIC Affiliate Partner as a disease oriented network in Ophthalmology.

ECRIN is the European Clinical Research Infrastructure Network and supports the conduct of independent, multinational clinical trials by managing and supporting clinical trials across borders, connecting networks, and advising and implementing policy, competitiveness and integration in European clinical research.
ECRIN Affiliate Partners are multinational disease-oriented networks who wish to maintain close contact and participate in collaborative projects and will jointly support multinational clinical studies in ophthalmology. serves as a resource to ECRIN-ERIC in the area of vision and ophthalmology clinical research, particularly providing scientific and medical expertise, access to patients and investigation capacity in ophthalmology.



Ongoing Services


1. Investigator Initiated Research

PROTOCOL nº: ECR-RET-2010-02 (study group detail)
TITLE: Identifying progression of retinal disease in eyes with NPDR in diabetes type 2 using non-invasive procedures.

PURPOSE: To identify eyes that show worsening and disease progression (progressor phenotypes). Identifier: NCT01145599


TITLE: Project Gullstrand - European Project for the Determination of Average Biometric Values of Human Eyes.

PURPOSE: To determine the average values of human ocular biometry and to correlate these values with visual function. Identifier: NCT01173614

TITLE: Neurodegeneration as an early event in the pathogenesis of Diabetic Retinopathy: A multicentric, prospective, phase II-III, double-blind randomized controlled trial to assess the efficacy of neuroprotective drugs administered topically to prevent or arrest Diabetic Retinopathy
PURPOSE: To assess whether neuroprotective drugs administered topically (somatostatin and brimonidine) are able to prevent or arrest the development and progression of neurodegenerative changes.

EU funded  FP7- HEALTH 2011 project: 278040-2

EudraCT Nº: 2012-001200-38 Identifier: NCT01726075


TITLE: Early onset of Neovascular Glaucoma

PURPOSE: To study the natural course of the disease, to determine risk factors for the occurrence of neovascular glaucoma and to identify biomarkers that better characterize the course of the disease. At the same time to test the efficacy of aganirsen for the treatment of neovascular glaucoma in about three hundred patients in 35 clinical centres across Europe.

EU funded FP7- HEALTH 2012 project: 305321



TITLE: European young investigators network for Usher syndrome
PURPOSE: Bring new insights towards the understanding of Usher Syndrome.

EU funded E-RARE 2 project: 12-058

Eur-USH Flyer

We are pleased to inform you that “EUR-USH” is inviting clinical sites to participate on a voluntary basis. 

If your Clinical Site is interested to participate please contact until 2014/12/12.

TITLE: Prospective, randomized, multicenter, open label, phase II/III study to assess efficacy and safety of ranibizumab 0.5 mg intravitreal injections plus panretinal photocoagulation (PRP) versus and PRP in monotherapy in the treatment of patients with high risk proliferative diabetic retinopathy.
PURPOSE: To compare efficacy and evaluate safety of intravitreal (ITV) injection of ranibizumab (0.5 mg) plus PRP versus PRP alone in the regression of retinal neovascularization (NV) in eyes with high-risk proliferative diabetic retinopathy (HR-PDR).


TITLE: Intraocular pressure and tolerability Study of Preservative Free Bimatoprost 0.03% Unit Dose (BUDPF) or preservative free Latanoprost 0.005% Unit Dose (LUDPF) (Monoprost) in patients with Ocular hypertension or glaucoma: A Randomized, single masked, 3 month cross-over, Investigator led, European multicentre Trial
PURPOSE: To investigate the efficacy and safety of BUDPF  and LUDPF in a clinical setting and may influence these drugs’ future use in Europe.

TITLE: A Collaborative Retrospective Trial on the Efficacy and Safety of intravitreal dexamethasone implant (Ozurdex) in patients with Diabetic Macular Edema (DME). THE EUROPEAN DME REGISTRAR STUDY
PURPOSE: To review  the safety and efficacy of injections with Ozurdex  (700 μg dexamethasone) in clinical practice management of patients with DME.

TITLE: A randomized, double-masked, sham-controlled phase 4 study of the efficacy, safety and tolerability of intravitreal aflibercept monotherapy compared to aflibercept with adjunctive photodynamic therapy in patients with plypoidal choroidal vasculopathy.
PURPOSE: To compare the efficacy and safety of intravitreal Aflibercept monotherapy with the efficacy and safety of combined treatment with Aflibercept associated with standard photodynamic therapy (PDT) with Verteporfin in age-related macular degeneration (AMD) patients with polypoidal choroidal vasculopathy (PCV) in a proof concept study.



 2. Industry-Driven Clinical Trials


TITLE: A prospective non-interventional study to assess the effectiveness of existing anti-vascular endothelial growth factor (anti-VEGF) treatment regimens in patients with diabetic macular edema (DME) with central involvement.

PURPOSE: To evaluate changes in visual acuity (ETDRS/Snellen) based on clinical management patterns and resource utilization in patients with DME with  central involvement starting treatment with an approved
anti-VEGF therapy.

TITLE: An open label, registry study of the safety of ILUVIEN® (fluocinolone acetonide 190 micrograms intravitreal implant in applicator)
PURPOSE: The study will assess the safety and usage in patients treated with ILUVIEN.


3. Certification for Refraction and Visual Acuity

3.1 Specific Agreements are celebrated according to the Sponsor request and study specificity.




2010 EVICR Network. All rights reserved.